Antibodies, proteins, and reagents for all your cancer research needs
Cancer is a complex multi-factorial disease; its development is triggered by a combination of genetic and environmental factors. Important hereditary factors include mutations in proto-oncogenes, tumor suppressor genes, and DNA damage repair components. Over the past decades much progress has been made in identifying fundamental cancer-predisposing mutations, such as those occurring in members of the BRCA gene family, and developing robust predictive genetic tests. Screening tests, such as mammography and PAP/HPV, have enabled the detection of early stage cancers thereby contributing to the reduction of cancer deaths (NIH 2015).
Although much progress has been made in terms of both cancer treatment and prevention, cancer still remains a global killer. According to the WHO, “Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades (WHO 2015).” Based on these statistics both basic and translational cancer research continue to be of the utmost importance.
In order to assist you with your research, Bio-Rad offers a comprehensive selection of cancer antibodies, cancer PrecisionAb™ antibodies for western blotting, proteins, and reagents for all of your research needs.
View Cancer PrecisionAb™ Antibodies
NIH National Cancer Institute (2015). Screening Tests. Available here, accessed July 15, 2015.
World Health Organisation (2015). Cancer Factsheet N°297. Available here, accessed July 15, 2015.
alamarBlue® is manufactured for Bio-Rad by Trek Diagnostic System. US. patent 5,501,959.
Payment methods we support: